DepoVax Technology Proves Effective in NIH-Sponsored Ebola Vaccine Study

The study, conducted in cynomolgus monkeys, explored several candidate vaccines from NIAID's preclinical services program.

Immunovaccine Inc. ("Immunovaccine") (IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease.

In this study four cynomolgus macaque subjects received two doses of the DepoVax-formulated vaccine, one at study initiation and a second on Day 56. They were then challenged on day 70 with a lethal dose of the wild type Zaire strain of the Ebola virus. The Zaire strain is believed to be the most lethal among Ebola viruses and is responsible for the current Ebola virus outbreak. More than two weeks following exposure to the virus, all vaccinated subjects were alive with no disease symptoms. The two control animals in this study succumbed to the infection within seven days.

Read the complete report here: http://on.mktw.net/1vfUDOk

Source: MarketWatch